<DOC>
	<DOC>NCT00254579</DOC>
	<brief_summary>CP-675,206 is a fully human monoclonal antibody (mAb). It binds to the CTLA4 molecule, which is expressed on the surface of activated T lymphocytes. CP-675,206 is thought to stimulate patients' immune systems to attack their tumors. CP-675,206 is not expected to have a direct effect on tumor cells. CP-675,206 been shown to induce durable tumor responses in patients with metastatic melanoma in Phase 1 and Phase 2 clinical studies.</brief_summary>
	<brief_title>Study of CP-675,206 in Refractory Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Surgically incurable Stage III or IV melanoma One prior systemic treatment for metastatic melanoma Measurable disease Eastern Cooperative Oncology Group (ECOG) PS = 0 or 1 Melanoma of ocular origin Received prior vaccine Received prior CTLA4inhibiting agent History of, or significant risk for, chronic inflammatory or autoimmune disease Potential requirement for systemic corticosteroids</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>refractory melanoma</keyword>
	<keyword>malignant melanoma</keyword>
</DOC>